Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Ovarian Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1

Interventions

Doxorubicin 14pembrolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Biopsy 9Cyclophosphamide 8X-Rays 7Radiotherapy 7Nivolumab 7Ifosfamide 7Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Temozolomide 5Radiation 5tazemetostat 4palbociclib 4Trabectedin 4Nuclear Medicine Department, Hospital 4Irinotecan 4Ipilimumab 4pazopanib 3larotrectinib 3fludarabine 3cabozantinib 3atezolizumab 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Proton Therapy 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Fluorodeoxyglucose F18 × 90 days × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡